

Ros, Javier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6289509/publications.pdf>

Version: 2024-02-01

26
papers

451
citations

758635

12
h-index

752256

20
g-index

26
all docs

26
docs citations

26
times ranked

582
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2022, 161, 90-98.	1.3	13
2	Ongoing and evolving clinical trials enhancing future colorectal cancer treatment strategies. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 235-247.	1.9	3
3	The Evolving Treatment Landscape in BRAF-V600E-Mutated Metastatic Colorectal Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 254-263.	1.8	13
4	Encorafenib plus cetuximab for the treatment of BRAF-V600E-mutated metastatic colorectal cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482211106.	1.4	4
5	Overcoming acquired MET amplification after encorafenib-cetuximab in BRAF-V600E mutated colorectal cancer. <i>European Journal of Cancer</i> , 2022, 172, 326-328.	1.3	5
6	Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2022, 172, 171-181.	1.3	14
7	Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study. <i>Clinical Cancer Research</i> , 2021, 27, 2515-2522.	3.2	39
8	Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. <i>Cancers</i> , 2021, 13, 1941.	1.7	21
9	Up-to-date role of aflibercept in the treatment of colorectal cancer. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1315-1324.	1.4	2
10	Myositis and myastheniform syndrome related to pembrolizumab. <i>BMJ Case Reports</i> , 2021, 14, e241766.	0.2	5
11	Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. , 2021, 9, e003370.		10
12	Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials. <i>European Journal of Cancer</i> , 2021, 155, 168-178.	1.3	1
13	BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199297.	1.4	38
14	The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2021, 22, 113.	1.3	9
15	Combined Treatment with Immunotherapy-Based Strategies for MSS Metastatic Colorectal Cancer. <i>Cancers</i> , 2021, 13, 6311.	1.7	30
16	Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern. <i>Autoimmunity Reviews</i> , 2020, 19, 102455.	2.5	51
17	Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria. <i>Clinical Cancer Research</i> , 2020, 26, 1846-1855.	3.2	70
18	Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093608.	1.4	37

#	ARTICLE	IF	CITATIONS
19	Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 653-664.	1.5	7
20	Clinical and Translational Challenges in Thyroid Cancer. <i>Current Medicinal Chemistry</i> , 2020, 27, 4806-4822.	1.2	6
21	Malignancy and myositis, from molecular mimicry to tumor infiltrating lymphocytes. <i>Neuromuscular Disorders</i> , 2019, 29, 819-825.	0.3	12
22	Triple-drug chemotherapy regimens in combination with an anti-EGFR agent in metastatic colorectal cancer - prospects from phase II clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 463-471.	1.9	7
23	Review of Immunogenomics and the Role of Tumor Mutational Burden as a Biomarker for Immunotherapy Response. <i>Journal of Immunotherapy and Precision Oncology</i> , 2019, 2, 144-151.	0.6	4
24	Cardiac tamponade and adrenal insufficiency due to pembrolizumab: a case report. <i>European Heart Journal - Case Reports</i> , 2018, 2, yty038.	0.3	21
25	DRESS syndrome due to vemurafenib treatment: switching BRAF inhibitor to solve a big problem. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2018-224379.	0.2	15
26	The safety of ramucirumab for the treatment of colorectal cancer. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 945-951.	1.0	14